Other Treatments for Alzheimer's Disease
Nymox has developed unique drug screening systems based on the research that led to its AlzheimAlert™ test, to identify other potential drug candidates for the treatment of Alzheimer's disease. Cells that over-express neural thread proteins start to degenerate and die prematurely. Nymox has screened compounds for their ability to impede the process of premature cell death brought about by neural thread proteins, and thus potentially slow or halt the loss of brain cells in the Alzheimer's disease brain. Nymox licensed this technology in 1997 from the Massachusetts General Hospital as part of a sponsored research and licensing agreement.
In still another approach to Alzheimer's therapeutics, Nymox is involved with work on new uses of known drugs. In November 1999, Dr. Ben Wolozin of Loyola University Medical Center in Chicago reported at the annual meeting of the Society for Neuroscience his findings that some members of a class of anti-cholesterol drugs called statins may delay or prevent the onset of Alzheimer's disease. This work was subsequently published in the peer-review literature (Arch Neurol 2000; 57: 1439-1443). Dr. Wolozin licensed the commercial and patent rights to this discovery to Nymox.
